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Introduction
We read with great interest the article by Navari &
Dazzan (2009) recently published in Psychological Medi-
cine. These authors found that antipsychotic treatment
may contribute to brain structural changes observed
in psychosis and that antipsychotics act regionally
rather than globally on the brain, with speciﬁc eﬀects
on diﬀerent brain structures.
In an own systematic review on the eﬀects of anti-
psychotics on the brain (Smieskova et al. in press) we
summarized ﬁndings from structural imaging studies
of schizophrenia. We focused on studies investigat-
ing schizophrenia patients using neuroimaging tech-
niques according to antipsychotic medication and
studies considering the diﬀerences in medication
either in various antipsychotic medications or over
the time or in various groups of patients. Overall,
we found that patients with schizophrenia receiv-
ing treatment with antipsychotics had reduced grey
matter (GM) volume, particularly in frontal and tem-
poral lobes. Medication with typical antipsychotics
also leads to increased volume of the basal ganglia,
while atypical antipsychotics reversed the eﬀect after
switching. Studies with typical antipsychotics have
reported increased GM volume in cingulate cortex,
in contrast to atypical antipsychotics with the excess
more often seen in thalamus volume.
Confounding eﬀects of antipsychotics
As discussed by Navari & Dazzan (2009), the potential
confounding impact of antipsychotics on progressive
brain changes in schizophrenia is considered contro-
versial (DeLisi, 2008). Although there is evidence for
GM loss and ventricular enlargement from prospec-
tive studies of patients with ﬁrst-episode and chronic
schizophrenia (Wood et al. 2008), most neuroimaging
studies of schizophrenia to date have not included the
examination of non-medicated patients, making con-
clusions about medication eﬀects on neuroimaging
measures diﬃcult. Investigation of subjects at the on-
set of the disease avoids potential confounders such
as antipsychotic treatment (Riecher-Rossler et al. 2007).
A clinical high-risk status for psychosis (at-risk mental
state, ARMS) is associated with a set of neurofunc-
tional abnormalities that are qualitatively similar to
those observed in patients with the disorder (Fusar-
Poli et al. 2007). As these ﬁndings are not attributable
to chronic psychotic symptoms or antipsychotic treat-
ment, they may solely represent markers of increased
vulnerability to psychotic disorders. Cross-sectional
structural MRI studies of non-medicated patients in a
prodromal phase of psychosis or ARMS demonstrated
that neuroanatomical abnormalities are already evi-
dent in the very early phase of psychosis (Wood et al.
2008) whereas longitudinal MRI studies found that the
subset of patients who developed psychosis showed
a longitudinal reduction in GM in the orbito-frontal,
temporal lobe, parietal lobe and cerebellum (Pantelis
et al. 2003 ; Job et al. 2005 ; Borgwardt et al. 2008).
Conclusions and future directions
Neuroimaging studies have provided compelling evi-
dence that despite antipsychotic medication (both
typical and atypical) there are detectable anatomical
changes at the level of total and regional brain vol-
umes. To date, it remains elusive whether the eﬀects of
antipsychotic medication on GM volume are simply
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beneﬁcial. Experimental studies of macaque monkeys
showed that chronic administration of either halo-
peridol or olanzapine was associated with smaller GM
volume (Konopaske et al. 2008). These results, if con-
ﬁrmed, raise ethical questions on antipsychotic use.
If antipsychotic medication may lead – at least in some
patients – to GM volume reduction careful beneﬁt–
risk decisions have to be made for individual patients.
Patients with schizophrenia should be very carefully
informed about the potential risks (and of course
beneﬁts) of antipsychotic medication.
It is questionable whether the eﬀects we are obser-
ving are the direct eﬀects of antipsychotics or due to
the illness process. Until we have more reliable studies
from non-medicated patients, the potential impact
of the confounding eﬀect of medication must be borne
in mind. For future studies, we therefore suggest
focusing on longitudinal designs that represent the
gold standard for investigation of medication eﬀects.
These studies clearly have the advantage of powerful,
within-subject designs. Small sample sizes, hetero-
geneity in the sociodemographic characteristics of
subjects, and lack of consistency between scanning
parameters should be addressed by future multi-site
studies that have shown the potential to overcome
most of these problems and to bridge basic neuro-
science with clinical psychiatry. So far, the investi-
gation of patients at risk or with a ﬁrst episode
of schizophrenia seems to be the most promising
alternative.
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